Perspective Therapeutics (CATX) Current Deferred Revenue (2024)
Perspective Therapeutics (CATX) reported Current Deferred Revenue of $1.4 million for Q4 2024, little changed sequentially from $1.4 million in Q3 2024.
Perspective Therapeutics (CATX) Current Deferred Revenue (2024) Analysis & Trends
Perspective Therapeutics (CATX) has 1 years of Current Deferred Revenue data on file, last reported at $1.4 million in Q4 2024.
- For the quarter ending Q4 2024, Current Deferred Revenue changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2024 stood at $1.4 million (changed N/A YoY), and the FY2024 full-year result was $1.4 million, changed N/A from the prior year.
- Current Deferred Revenue held at $1.4 million in Q4 2024, from $1.4 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.4 million in Q1 2024 to a low of $1.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.40 Mn |